About Beam Therapeutics
Industry:
Gene Editing/Biotechnology
Founded:
2017
Founders:
David Liu, Feng Zhang, Keith Joung
Status:
Public (NASDAQ: BEAM)
Funding & Growth
Total Raised:
$1B+
Valuation:
$2B+ market cap
Stage:
Public
Key Investors:
ARCH Venture Partners
F-Prime Capital
GV
✓ Pros
- • Next-gen base editing technology
- • World-class scientific founders
- • Strong IP portfolio
- • Well-funded pipeline
- • Innovative culture
✗ Cons
- • Pre-revenue stage
- • High expectations
- • Competitive hiring market
- • Long R&D timelines